.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB08_Icotinib.Icotinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB08_Icotinib.Icotinib| name: | Icotinib |
| ATC code: | L01EB08 | route: | oral |
| n-compartments | 1 |
Icotinib is an orally administered, small-molecule tyrosine kinase inhibitor that selectively inhibits the epidermal growth factor receptor (EGFR). It is used primarily for the treatment of non-small cell lung cancer (NSCLC) and is approved in China for this indication.
Pharmacokinetic parameters reported in Chinese adult patients with advanced non-small cell lung cancer after oral administration of icotinib tablets.
Hu, P, et al., & Jiang, J (2015). Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect. European journal of clinical pharmacology 71(7) 843–850. DOI:10.1007/s00228-015-1864-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25995169